PCI Biotech announced that results from preclinical studies on tuberculosis performed in collaboration with The University of Zurich and ETH Zurich are accepted for publication in Frontiers in Immunology, a high impact immunology journal. The article title is 'Photochemically-mediated inflammation and cross-presentation of Mycobacterium bovis BCG proteins stimulates strong CD4 and CD8 T-cell responses in mice'.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.618 NOK | -0.12% | -4.82% | -22.77% |
1st Jan change | Capi. | |
---|---|---|
-22.77% | 5.47M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- PCIB Stock
- News PCI Biotech Holding ASA
- PCI Biotech Announces Publication of Preclinical Tuberculosis Results